Ardelyx (ARDX) is a small-cap biotech company with two first-in-class therapies: IBSRELA for IBS-C and XPHOZAH for CKD patients on dialysis. Valued at $1.07 billion, Ardelyx stock has returned 542% over three years, with Q1 revenue up 61% year-over-year to $74.1 million. IBSRELA sales reached $44.4 million, reinforcing its position in the market.

Ardelyx reaffirmed IBSRELA’s 2025 U.S. net sales guidance of $240 million to $250 million, aiming for over $1 billion in peak annual sales. XPHOZAH also showed growth, with net sales of $23.4 million, up 55% year over year. Despite revenue growth, the company reported a net loss of $41.1 million in Q1.

Analysts predict Ardelyx’s revenue will increase by 9.2% in 2025 and by 32.8% in 2026, with an expected profit of $0.05 per share by 2026. Wall Street analysts rate the stock a “Strong Buy,” with a target price of $10.73, indicating 139% upside potential and the potential for a 10x return within five years for long-term investors.

With growing revenue and market share, Ardelyx is transitioning from a clinical-stage biotech to a commercial force in gastrointestinal and renal therapeutics. While not profitable yet, the company’s billion-dollar peak sales potential for IBSRELA and XPHOZAH suggests promising growth opportunities for long-term investors with a high risk tolerance.

Read more at Yahoo Finance: This Small-Cap Stock Could 10x by 2030, But It’s Not for the Faint of Heart